Meanwhile, it has also been found activation of intestinal FXR induces the expression of FGF15/19, which leads to SHP phosphorylation, thus recruiting DNA methyltransferase 3A to bind to lipid-producing genes, inhibiting hepatic steatosis (Kim et al., 2020). This evidence concerns the gene NR0B2 and fatty liver disease.